Biotech Start-Up Case Study 1: Company A: Navigating Capital, Policy, and Global Biotech Scale-Up

Company A emerged from a promising biotechnology platform built around advanced biocatalysis technology originating from publicly funded research. Like many deep-tech spinouts, the company began with a strong scientific foundation and early-stage public funding support. At first glance, the pathway to commercial success appeared straightforward: compelling science, protected intellectual property, and a clear technological advantage. However, the realities of scaling a biotech company quickly revealed themselves to be far more complex than anticipated. 

As the company matured, it became evident that local funding mechanisms alone were insufficient to support a high-risk, capital-intensive biotech venture with global ambitions. To unlock international investment and gain access to specialised expertise, markets, and regulatory environments, the business pursued an internationalisation strategy, establishing a mirror structure offshore to attract European capital. While commercially necessary, this move introduced significant regulatory and political scrutiny due to the transfer of publicly funded intellectual property beyond South Africa’s borders. 

The company’s experience highlighted a lesson often overlooked in biotech entrepreneurship: commercial success depends as much on funding structures, regulatory ecosystems, and policy alignment as it does on scientific excellence. Leadership was forced to navigate competing pressures from investors, policymakers, and institutional stakeholders, while simultaneously trying to build a globally competitive business in an emerging innovation environment with few precedents.

Ultimately, adaptation proved critical to survival. Rather than remaining fixed to an original model, the company repositioned itself geographically and strategically, relocating operations internationally and pivoting from a platform technology business into therapeutic biopharmaceutical development. The business raised substantial international capital, operated for more than a decade, and progressed into advanced clinical development, demonstrating that locally developed biotechnology can compete on a global stage when supported by the right commercial strategy. 

Navigating Capital, Policy, and Global Biotech Scale-Up

Perhaps the most enduring lesson from Company A is that intellectual property alone is never enough. Successful biotech commercialisation requires careful alignment between capital, policy, regulatory strategy, manufacturing readiness, and long-term market positioning. In deep-tech entrepreneurship, adaptability is often more valuable than certainty